Drug
Lumateperone clinical trials
Also written ITI-007 and Caplyta.
- studies test it
- 34
- open now
- 12
- in phase 3
- 19
- first study started
- 2011
Keep track of what changes. Save the lumateperone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2023 | 3 |
| 2024 | 8 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 19
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 11
Intra-Cellular Therapies, Inc. (23) · University of Chicago (1) · Watim Medical & Dental College (1) · University of Texas at Austin (1) · Eric Lenze (1) · Jason Careri (1) · Massachusetts General Hospital (1) · CSTrials Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lumateperone is read from its arms, and is right about nine times in ten.
Testing it · 34
- This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse EffectsNot yet recruitingPhase 4Watim Medical & Dental CollegeNCT07676669Written as Lumateperone
- Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT05850689Written as Lumateperone
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06229210Written as Lumateperone
- Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsRecruitingPhase 3Intra-Cellular Therapies, Inc.NCT06372964Written as Lumateperone
- Lumateperone for Late-Life DepressionRecruitingPhase 3Eric LenzeNCT07623135Written as Lumateperone
- Caplyta Versus Placebo for Adults With Social Anxiety DisorderRecruitingPhase 4Jason CareriNCT07799493Written as Lumateperone 42 mg
- The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar DepressionRecruitingPhase 4Massachusetts General HospitalNCT07699445Written as Lumateperone 42 mg
- A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderNot yet recruitingPhase 3Intra-Cellular Therapies, Inc.NCT07747389Written as Lumateperone
- Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency DisorderRecruitingPhase 2CSTrials Inc.NCT07734103Written as Lumateperone (ITI-007)
- Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With SchizophreniaRecruitingPhase 4University of Massachusetts, WorcesterNCT06174116Written as Lumateperone
- Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life AbuseNot yet recruitingPhase 4University of Texas at AustinNCT07369115Written as Lumateperone 42 mg
- Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.RecruitingPhase 3Louisiana State University Health Sciences Center ShreveportNCT06482554Written as Lumateperone 42 mg
- Lumateperone for the Prevention of Relapse in Patients With SchizophreniaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT04959032Written as Lumateperone 42 mg
- Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective DisorderCompletedPhase 1Intra-Cellular Therapies, Inc.NCT06627413Written as Lumateperone Capsule
- Caplyta in Borderline Personality DisorderCompletedPhase 2University of ChicagoNCT05356013Written as Caplyta
- Study of Lumateperone in the Acute Treatment of Patients With Bipolar ManiaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT06462586Written as Lumateperone
- Study of Lumateperone in the Treatment of Patients With Bipolar ManiaCompletedPhase 3Intra-Cellular Therapies, Inc.NCT06462612Written as Lumateperone
- Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum DisorderCompletedPhase 1Intra-Cellular Therapies, Inc.NCT06557902Written as Lumateperone 10.5 mg capsule
- Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective DisorderCompletedPhase 1Intra-Cellular Therapies, Inc.NCT04779177Written as Lumateperone 42 mg
- Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar DepressionCompletedPhase 3Intra-Cellular Therapies, Inc.NCT02600494Written as ITI-007 (Lumateperone)
Codes
What other systems call lumateperone · ClinicalTrials.gg INT001287
- MeSH (NLM) C000705749lumateperoneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 70BSQ12069LUMATEPERONEConfirmed FDA, NLM
- RxNorm 2275602One source FDA
- NCI Thesaurus C166975LumateperoneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705749 | lumateperone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 70BSQ12069 | LUMATEPERONE | Confirmed FDA, NLM |
| RxNorm | 2275602 | — | One source FDA |
| NCI Thesaurus | C166975 | Lumateperone | One source FDA |
Also registered as lumateperone tosylate (UNII JIE88N006O · RxNorm 2275731).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.